Tvardi Therapeutics (TVRD) CFO Conn received 45,000 units
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Avi Daniel Conn (Chief Financial Officer at Tvardi Therapeutics Inc., TVRD) reported that they received 45,000 units on Jan 29, 2026.
- Reporting person
- Conn Avi Daniel
- Role
- Chief Financial Officer
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 29, 2026 | Grant or award (A) | Employee Stock Option (right to buy)On 45,000 Common Stock1 | +45,000 | - | - | 45,000 direct |
Holdings before and after
- Employee Stock Option (right to buy): 0 to 45,000 direct
Footnotes from the filing
- 1. The shares subject to the option shall vest and become exercisable in equal monthly installments over 48 months commencing on January 29, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Conn report in this TVRD Form 4?
Avi Daniel Conn (Chief Financial Officer at Tvardi Therapeutics Inc., TVRD) reported that they received 45,000 units on Jan 29, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for TVRD
Across the 5 sessions after earlier TVRD headlines, the stock closed higher 3 times and lower 2 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TVRD | SPY |
|---|---|---|---|
| Jan 9, 2026 | Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | +7.6% | +0.7% |
| Jan 8, 2026 | Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights | +8.7% | -0.0% |
| Nov 18, 2025 | Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference | +2.2% | -0.8% |
| Nov 14, 2025 | Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update | -1.9% | -0.0% |
| Nov 4, 2025 | Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | -2.7% | -1.2% |
Earlier insider filings at TVRD
- Feb 2, 2026SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul
- Feb 2, 2026SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.
- Feb 2, 2026SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin
- Dec 18, 2025SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin
- Dec 18, 2025SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel
Quantisnow market dataNASDAQ
TVRD
Tvardi Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for TVRD
Full TVRD profile on Quantisnow Follow TVRD and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time